Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors from the central anxious program, conolidine modulates alternate molecular targets. A Science Advances research discovered that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://danielb316xmy0.dekaronwiki.com/user